The FTSE 100 drugs firm will pay gene therapy group Oxford Biomedica £15m up front to scale up manufacturing capacity of the vaccine, as it hopes to win fast-track approval in the US.
Astra seals deal to mass produce its Covid jab, as it begins US trials
Something you may find interesting…
[recent_products per_page="4" columns="4" orderby="rand" order="rand"]